Biotech China 2014

Leukemia: University of Texas, MD Anderson

Total Score People Score Events Score
60 48 15
Date Event Presentation Speakers
May 31, 2013 ASCO Annual Meeting 2013 Management of Chronic Lymphocytic Leukemia (M10) William G. Wierda
Education Sessions Anas Younes
Education Sessions John de Groot
Special Session Razelle Kurzrock, Gabriel N Hortobagyi
Education Sessions Robert L. Coleman
Educations Sessions Jeffrey E Gershenwald, Stanley Hamilton
April 6, 2013 AACR Annual Meetings Drug Discovery in Industry, Academia, and Government: What Is the Track Record? Michael A. White
Clinical Trial Design in the Genomic Era Co-Chairpersons: Donald A. Berry, The University of Texas MD Anderson Cancer Center, Houston, TX, and George W. Sledge, Jr., Stanford University School of Medicine, Stanford, CA Donald Berry
Rational Combination Therapies in Cancer Chairperson: Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX Gordon Mills
Bridging the Gap Between Clinical Research and Laboratory Investigation: Utilizing Presurgical Clinical Trials to Investigate Anti-CTLA-4 Immunotherapy Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX Padmanee Sharma
Whole Body Metabolism and Cancer Chairperson: Philipp E. Scherer, UT Southwestern Medical Center, Dallas, TX Philipp Scherer
Tumor-Secreted Factors Chairperson: David C. Lyden, Weill Cornell Medical College of Cornell University, New York, NY George A. Calin
Identifying Novel Redox Signaling Pathways for Cancer Chemoprevention: From Fly to the Mouse Garth Powis, The University of Texas MD Anderson Cancer Center, Houston, TX Garth Powis
PAK Family of Kinases in Human Cancer: Past, Present, and Future Rakesh Kumar, George Washington University, Washington, DC Rakesh Kumar
August 24, 2012 21st Annual Short Course on Experimental Models of Human Cancer P53 Guillermina Lozano
December 13, 2011 New Horizons in Cancer Research: Biology to Prevention to Therapy Genomic alterations in gingivobuccal cancer: Results from whole-exome resequencing Sadhan Majumder
Prostaglandin E2 promotes intestinal tumor growth via DNA methylation Raymond N DuBois
Plenary Session 5 | Cancer Prevention and Chemoprevention Raymond N DuBois
Day in Review Raymond N DuBois
Session 4 | Molecular Epidemiology of Cancer: Towards Personalized Risk Assessment, Prevention, and Therapy Xifeng Wu
July 30, 2011 MD Anderson Physicians Network Symposium Changing Paradigms in Cancer Treatment and Patient Management Non-Small Cell Lung Cancer | Combined Modality Therapy for Patients with Stage II/III Disease Scott M Lippman
Making Sense of Multigene Assays in Practice Ana Gonzalez-Angulo
HER-2 Directed Therapies: Adjuvant or Neoadjuvant? Ana Gonzalez-Angulo
Challenging Case Presentations and Interactive Audience Participation Deborah Kuban
Dose Escalation and Stereotactic Therapy in the Management of Pancreatic Cancer Sunil Krishnan
Active Surveillance vs. Treatment in the Management of Prostate Cancer Deborah Kuban
Molecular Markers Guiding Diagnosis and Optimizing Management of Leukemias Stefan Faderl
Emerging Paradigms in the Management of Myeloproliferative Disorders Stefan Faderl
New Therapeutic Targets in Lymphoma | The B-cell Receptor, CD-30 Fredrick B Hagemeister
PET Scan in Lymphoma: Which Histologies? When? Can it Guide Treatment? Fredrick B Hagemeister
Advances in RT: IMRT, Short Course and Selective Omission of RT Sunil Krishnan
February 17, 2011 15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma How I Manage Relapsed/Refractory Chronic Lymphocytic Leukemia William G. Wierda
Comment William G. Wierda
HDAC Function and HDAC Inhibitors: Where Is the Selectivity? Jean-Pierre Issa
Epigenetics and the Biology of Hematologic Malignancies Anas Younes
Afternoon Workshop | Epigenetics and Gene Expression Anas Younes
Comment Jean-Pierre Issa
The Nature of Future MoAbs in Leukemia William G. Wierda
Non-Hodgkin Lymphoma: Conjugated and Nonconjugated MoAbs Anas Younes
Chronic Lymphocytic Leukemia William G. Wierda
Acute Myeloid Leukemia | Myelodysplastic Syndromes Jean-Pierre Issa
April 30, 2010 Great Debates and Updates in Hematologic Malignancies Debate: What is the most appropriate salvage therapy for post-imatinib failure in CML? Jorges Cortes
Debate: What is the best tyrosine kinase inhibitor for frontline therapy of CML? Hagop M. Kantarjian
Debate: How should bisphosphonates be utilized in multiple myeloma patients responding to frontline therapy? Robert Z. Orlowski
Evolving and promising therapeutic strategies for post-TKI failure in CML Hagop M. Kantarjian
Debate: For newly diagnosed multiple myeloma patients who relapse from a ≥VGPR response more than 12 months following frontline therapy, what is the best salvage strategy? Robert Z. Orlowski
What is the role of allogeneic transplantation in myeloproliferative neoplasms Jorges Cortes
Debate: How prominent should the roles of lenalidomide, bendamustine and ofatumumab be in the frontline therapy of CLL? Susan O’Brien
Debate: FCR is the best frontline therapy for CLL patient ≥65 years of age Susan O’Brien
Debate: What is the best frontline therapy for intermediate-2 and high risk MDS? Jorges Cortes
Debate: What is the best therapy for MDS patients with deletion 5q? Guillermo Garcia-Manero
Novel and evolving therapeutic strategies for MDS Guillermo Garcia-Manero
April 10, 2010 Practical Updates in Oncology Therapeutic Options in Ovarian Cancer Robert L. Coleman
Advances in Chronic Lymphocytic Leukemia William G. Wierda
Targeted Therapies for Gastrointestinal Malignancies Cathy Eng
Treatment Advances in SCLC and NSCLC Joan H Schiller
Lunch/Ethics Lecture Michael S Ewer
November 6, 2009 Translating Scientific Advances Into Clinical Care for Cancer Multiple Myeloma Robert Z. Orlowski
September 11, 2009 Sixth Annual Symposium on Controversies and Clinical Challenges In Lymphoma, Myeloma, and Leukemia Postsession Survey and Case-Based Panel Discussion: Applying Principle to Practice Stefan Faderl
Clinical Challenges in CLL Stefan Faderl
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Crystallographic Studies of CYP46A1 Irina A. Pikuleva
June 27, 2008 American Society of Clinical Oncology Welcome & Introductions J. L. Abbruzzese
Program Commitee J. L. Abbruzzese, Cathy Eng, Hagop M. Kantarjian
May 30, 2008 ASCO Annual'08 Meeting breast cancer-- Postmenopausal Hormone Therapy: Friend or Foe? (M19) Peter Ravdin
cancer genetics-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun Margaret R. Spitz
cancer prevention/epidemiology-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun Margaret R. Spitz
cancer prevention/epidemiology-- Postmenopausal Hormone Therapy: Friend or Foe? (M19) Peter Ravdin
developmental therapeutics-- c-MET Inhibition for Cancer Treatment Razelle Kurzrock
developmental therapeutics-- Issues in the Modulation of Angiogenesis Pathways (M10) Roy S. Herbst
developmental therapeutics-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials? Chris H. Takimoto
gastrointestinal (colorectal) cancer-- Advances in Anal Cancer Management (M01) Cathy Eng
gastrointestinal (colorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy Cathy Eng
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A) James C. Yao
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B) James C. Yao
gastrointestinal (noncolorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy Cathy Eng
gastrointestinal (noncolorectal) cancer Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials? Chris H. Takimoto
genitourinary cancer-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies CPO20A) Paul Mathew
genitourinary cancer What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B) Paul Mathew
gynecologic cancer-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20) Maurie Markman
lung cancer-- Therapeutic Modalities for “Small” Stage I Lung Cancers Robert Timmerman
lymphoma and plasma cell disorders-- The Role of Maintenance Therapy in Follicular Lymphoma: Pros and Cons Peter McLaughlin
patient and survivor care-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20) Maurie Markman
patient and survivor care-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials? Chris H. Takimoto
sarcoma/bone and soft tissue cancers-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12) Shreyaskumar Patel
tumor biology-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12) Shreyaskumar Patel
meet the professor sessions-- Advances in Anal Cancer Management (M01) Cathy Eng
meet the professor sessions-- Issues in the Modulation of Angiogenesis Pathways (M10) Roy S. Herbst
meet the professor sessions-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20) Maurie Markman
meet the professor sessions-- Postmenopausal Hormone Therapy: Friend or Foe? (M19) Peter Ravdin
meet the professor sessions-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12) Shreyaskumar Patel
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A) James C. Yao
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B) James C. Yao
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20A) Paul Mathew
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B) Paul Mathew
March 25, 2008 CANCER MOLECULAR MARKERS Non Coding RNAs Involvement in Cancer Predisposition and Tumor Development George A. Calin
October 11, 2007 Sixth International Colorectal Cancer Congress Role of uPAR in Colorectal Cancer Lee M Ellis
Unexpected Findings in Angiogenesis Research Lee M Ellis
Should Anti-VEGF Therapy Continue Beyond Progession? Lee M Ellis
Angiopoietin Inhibitors Chris H. Takimoto
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.